MRI contrast developer Epix Medical reported fiscal 2004 first-quarter revenues of $3.6 million, compared with $3.5 million in sales recorded for the same period in fiscal 2003.
For the period (end-March 31), the Cambridge, MA-based firm had a net loss of $3.9 million, substantially less than the net loss of $5.4 million reported for the 2003 fiscal first quarter.
By AuntMinnie.com staff writersApril 30, 2004
Related Reading
Epix names McMurry as research VP, March 12, 2004
Epix loss falls, sales rise in 2003, February 18, 2004
Epix gets U.S. patent for MS-325, January 13, 2004
Epix submits MR contrast agent for FDA approval, December 16, 2003
Epix COO resigns, November 11, 2003
Copyright © 2004 AuntMinnie.com
